With a market capitalization (market cap) of $6.06B — a measure of how much the company is worth — Kiniksa Pharmaceuticals International, plc is the 1280th most valuable company in Healthcare as of August 18, 2026. Shares trade at $79.49, up +0.39% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Visit websiteAs of August 18, 2026, Kiniksa Pharmaceuticals International, plc (KNSA) is worth $6.06B — this is its market capitalization, the total value of all its outstanding shares.
Kiniksa Pharmaceuticals International, plc’s market cap is $6.06B, which ranks it #1280 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Kiniksa Pharmaceuticals International, plc (KNSA) shares trade at $79.49, up 0.39% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Kiniksa Pharmaceuticals International, plc trades at a price-to-earnings (P/E) ratio of 99.4, based on its latest share price and annual earnings per share.